NovAliX proposes fragment-based drug discovery programs using its Fragments Analysis by MAss Spectrometry (FAMASS™) technology in combination with its in-house developed or customer fragment library.
NovAliX proposes this cost-effective approach for fast lead generation using its platform to identify fragments and then growing these compounds into potential drug candidates through its medicinal chemistry and structural biology capabilities.
